Name: Latest research reports of Natco Pharma Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Natco Pharma Ltd.
Rating: 5
Author: ICICI Securities Limited

Natco Pharma Ltd.

NSE: NATCOPHARM | BSE: 524816 | ISIN: INE987B01026 | Industry: Pharmaceuticals
| Value Stock, Under Radar

822.5500 16.00 (1.98%)

NSE Oct 03, 2025 15:31 PM

45.35% Fall from 52W High

Volume: 331.0K

Natco Pharma Ltd.

31 May 2017

822.55

1.98%

Natco Pharma Limited

Buy: Natco Pharma Ltd.

Target

ICICI Securities Limited

EBITDA margins improved 1810 bps YoY to 41.7% (I-direct estimates: 38.5%) mainly due to Oseltamivir exclusivity. EBITDA grew 159% to | 241 crore (I-direct estimate: | 215 crore) Adjusted net profit increased 178% YoY to | 177 crore (I-direct...

Natco Pharma Ltd. has lost -39.25% in the last 1 Year